Insilico Medicine IP Limited

Glaxosmithkline Intellectual Property Development Limited

Nio Technology (anhui) Co., Ltd.

F. Hoffmann-la Roche Ag

Xiao Ding

Wei Zhu

Hong Shen

Zehong Wan

Xuefei Tan

Fabian Dey

Feng Ren

Mingwei Zhou

Yingxia Sang

Luigi Piero Stasi

Jianyu Xu

Liena Qin

Qian Liu

Baowei Zhao

Weiqiang Xing

Hailong Wang

Yimin Hu

Chengang Zhou

Yang Zhan

Kai Long

Houguang Shi

Colin Michael Edge

Hongfu Lu

Yun Jin

Yan A Ivanenkov

Fang Han

Yongqiang Liu

Chunhai Li

Jingjing Peng

Jinxin Liu

Jiachen Zhang

Wanli Shao

Huaxing Yu

Xiaosong Liu

Chiachun Chen

Jianfei Wan

Qiongfeng Xu

Xiaoyu Ding

Bogdan Zagribelnyy

The disclosure relates to the field of electric vehicles, and in particular provides a vehicle refrigerator control method, a storage medium, and a vehicle, aiming to solve the problems of how to implement the intelligent identification of items stored in a vehicle refrigerator, and of controlling the vehicle refrigerator based on information of the stored item and vehicle state information. To this end, the method of the disclosure includes: obtaining item information of a vehicle refrigerator; obtaining a real-time temperature and a target temperature of the vehicle refrigerator; obtaining vehicle state information; and controlling the vehicle refrigerator based on the real-time temperature, the target temperature, and the vehicle state information. By applying the method of the disclosure, the user can quickly and accurately know the information of the item stored in the vehicle refrigerator, a suitable target temperature can be automatically set based on the item information, and the vehicle refrigerator can be controlled, based on the vehicle state information, to operate in different modes. The method of the disclosure not only optimizes the control over the vehicle refrigerator, satisfies the refrigeration requirement, but also solves the problems of NVH and vehicle energy consumption, etc, thereby providing users with a more comfortable experience.

Vehicle refrigerator control method, storage medium, and vehicle

Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of anemia.

Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof

The disclosure provides for compounds and methods for modulating or inhibiting TEAD. Further provided herein are pharmaceutical compositions comprising the TEAD inhibitors and methods of treatment using the TEAD inhibitors or the pharmaceutical compositions.

TEAD inhibitors and methods of uses thereof

Described herein are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.

Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof

Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of inflammatory bowel disease.

Described herein are MAT2A inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with MAT2A.

Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof

Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.

SARS-CoV-2 inhibitors for treating coronavirus infections

Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Substituted fused pyrazole compounds and their use as LRRK2 inhibitors

Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

Compounds

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

LRRK2 inhibitors for the treatment of Parkinson's disease

Compounds as LRRK2 kinase inhibitors

Growing community of inventors

Shanghai, China

Xiao Ding